Treatment for Chickenpox
For otherwise healthy children with chickenpox, routine antiviral treatment is not recommended; however, oral acyclovir should be considered for high-risk groups including persons aged >12 years, those with chronic skin or lung conditions, and those on long-term salicylate therapy or corticosteroids, when administered within 24 hours of rash onset. 1
Treatment Approach by Patient Population
Immunocompromised Patients
- Intravenous acyclovir is the treatment of choice when administered within 24 hours of rash onset 1
- This has been demonstrated to effectively reduce varicella-associated morbidity and mortality in this population
- Treatment duration: typically 5-10 days 2
Otherwise Healthy Children (<12 years)
- Routine acyclovir is NOT recommended 1
- The AAP determined that clinical benefit is insufficient to justify routine administration in healthy children
- While FDA-approved oral acyclovir reduces fever duration, number of lesions, and symptom severity, it does not decrease transmission or reduce school absence
- Supportive care remains the mainstay
Adolescents and Adults (≥12 years)
- Oral acyclovir is recommended at 800 mg five times daily for 5 days 1
- Must be initiated within 24 hours of rash onset for effectiveness
- Clinical trials demonstrate acyclovir is well-tolerated and effective in reducing duration and severity of illness in this age group
High-Risk Otherwise Healthy Patients
Consider oral acyclovir for: 1
- Persons aged >12 years
- Chronic cutaneous (skin) disorders
- Chronic pulmonary (lung) disorders
- Long-term salicylate therapy (aspirin)
- Short, intermittent, or aerosolized corticosteroid courses
- Secondary household contacts (some experts recommend)
Pregnant Women
- Routine oral acyclovir is NOT recommended due to unknown fetal risks 1
- Acyclovir is FDA Category B (animal studies show no harm, but inadequate human studies)
- However, intravenous acyclovir SHOULD be considered for serious viral complications such as pneumonia 1
- A registry of 596 first-trimester exposures showed birth defect rates similar to the general population
Neonates
- Intravenous acyclovir for 5-10 days is effective when begun early 2
- Particularly critical for neonates whose mothers developed chickenpox 5 days before to 2 days after delivery
Critical Timing Considerations
The 24-hour window is crucial: Acyclovir effectiveness depends entirely on administration within 24 hours of rash onset 1. After this window, clinical benefit is substantially diminished.
Common Pitfalls to Avoid
- Do not use acyclovir for prophylaxis after exposure in otherwise healthy individuals—vaccination is the method of choice 1
- Avoid antibiotics unless secondary bacterial infection is documented—17% of providers inappropriately prescribe antibiotics 3
- Do not delay treatment in immunocompromised patients waiting for confirmation—initiate within 24 hours of rash onset
- Avoid aspirin in children with chickenpox due to Reye's syndrome risk
Supportive Care Measures
For all patients, regardless of antiviral use:
- Antipyretics (acetaminophen, NOT aspirin in children)
- Antihistamines for pruritus
- Maintain hydration
- Keep fingernails short to prevent secondary bacterial infection from scratching
- Isolation until all lesions are crusted
Post-Exposure Prophylaxis (Different from Treatment)
This is distinct from treating active disease: